It has been widely used in patients with rheumatoid arthritis and psoriasis, significantly reducing serum levels of IL‐6, TNF‐α and IFN‐γ.9, 10 In a phase III clinical trial in patients with moderate‐to‐severe psoriasis conducted in India, itolizumab was effective and well tolerated.11 Here, TNF is linked to psoriasis.